Lara Longpre - Sep 10, 2019 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
Sep 10, 2019
Transactions value $
-$10,417
Form type
4
Date filed
3/18/2024, 05:40 PM
Next filing
May 12, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Purchase $10.3K +965 +0.92% $10.64 105K Sep 10, 2019 Direct F1
transaction MIRM Common Stock Sale -$20.7K -1K -0.95% $20.62 104K Jan 9, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F2 Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units.